Tag Archives: Rova-T

Patients lose, lawyers win, as AbbVie does deal with Amgen to delay Humira biosim.

The News: Amgen Inc. (Thousand Oaks CA) has agreed to delay the US launch of its FDA-approved biosimilar version of AbbVie Inc.’s (North Chicago) Humira (adalimumab) until 2023, under a… Read more »

AbbVie Agrees to Buy Stemcentrx, Reports Jump in Earnings

U.S. biopharmaceutical firm AbbVie Inc. (North Chicago) on Thursday said it will acquire cancer biotech company Stemcentrx Inc. (South San Francisco) in a roughly $5.8 billion cash and stock deal that would expand… Read more »